Squarepoint Ops LLC Cuts Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Squarepoint Ops LLC lessened its position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 82.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,319 shares of the company's stock after selling 78,969 shares during the period. Squarepoint Ops LLC's holdings in Kura Oncology were worth $336,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. ProShare Advisors LLC lifted its position in Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company's stock valued at $384,000 after purchasing an additional 1,588 shares during the period. Aaron Wealth Advisors LLC lifted its position in Kura Oncology by 2.4% during the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company's stock valued at $1,444,000 after purchasing an additional 1,673 shares during the period. Hsbc Holdings PLC lifted its position in Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company's stock valued at $374,000 after purchasing an additional 2,167 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Kura Oncology by 17.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company's stock valued at $430,000 after purchasing an additional 2,940 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kura Oncology by 34.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,060 shares of the company's stock valued at $372,000 after purchasing an additional 4,654 shares during the period.

Kura Oncology Price Performance

Shares of NASDAQ KURA traded up $0.34 during midday trading on Friday, reaching $18.58. The stock had a trading volume of 499,446 shares, compared to its average volume of 913,140. The stock has a 50-day moving average of $19.59 and a 200-day moving average of $20.30. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -8.33 and a beta of 0.84. Kura Oncology, Inc. has a 12-month low of $7.41 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.04. The firm's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.53) earnings per share. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on KURA. JMP Securities restated a "market outperform" rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus reduced their target price on shares of Kura Oncology from $28.00 to $26.00 and set a "buy" rating for the company in a report on Friday, August 9th. StockNews.com cut shares of Kura Oncology from a "hold" rating to a "sell" rating in a report on Thursday, August 22nd. Wedbush reaffirmed an "outperform" rating and set a $37.00 target price on shares of Kura Oncology in a report on Friday, August 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of "Moderate Buy" and an average price target of $30.60.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.